JAZZ PHARMACEUTICALS FRANCE
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
- Conditions
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 476
- Registration Number
- NCT02348606
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Preferred Research Partners, Little Rock, Arkansas, United States
🇺🇸So Cal Institute For Respiratory Diseases, Inc., Los Angeles, California, United States
An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.
- Conditions
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT02325011
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
- Conditions
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT02269579
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Shands Cancer Hospital @ University of Florida, Gainesville, Florida, United States
🇺🇸John Theurer Cancer Center @ Hackensack Medical University Medical Center, Hackensack, New Jersey, United States
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02257684
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT02238925
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
- Conditions
- Interventions
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT02224560
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT02224703
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
- Conditions
- Interventions
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT02224690
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 106
- Registration Number
- NCT02221869
- Locations
- 🇺🇸
Stanford Sleep Medicine Center, Redwood City, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸UT/LeBonheur Neuroscience Institute, Memphis, Tennessee, United States
An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
- Conditions
- Interventions
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT02150928
- Locations
- 🇪🇸
Hospital of Navarra, Pamplona, Navarra, Spain